|
BioSquare preliminary program:
Opening Session - “Top Views on Bioconvergence”
Monday February 1st, 2010 - 11:15 - 12:00
Pharmaceuticals, biotech, nanotech, in silico, diagnostics and medical devices companies increasingly need one another to advance their clinical programs. This bioconvergence of innovative technologies has the potential to revolutionize medical care.
Speakers: - Patrick Aebischer, President, EPFL
- G. Steven Burrill, CEO, Burrill & Co
- Elmar Schnee, President, Merck Serono
- Paul Stoffels, Group Chairman, Global R&D, Johnson and Johnson
- Christopher Viehbacher, CEO, sanofi-aventis
“Global Health: Neglected Diseases and the Big Three, how the industry can help?”
Monday February 1st, 2010 - 14:00 - 14:45
Pharmaceutical leaders, PDPs and multilateral organizations representatives will constitute a panel and discuss on the best approaches on the Big 3: “HIV - Malaria - Tuberculosis” and neglected diseases.
Speakers: - James Geraghty, Sr VP, Genzyme
- Patrick Nef, VP, Business Development, Medicines for Malaria Ventures
- Jean-Pierre Paccaud, Director, Business Development, DNDi
- Robert Sebbag, Vice President Access to Medicines, sanofi-aventis |
